Search clinical trials for: Fluticasone Propionate Placebo

Total 54724 results

Eurofarma Laboratorios S.A.

Not yet recruiting

Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR) (TRIPLAR)

Chronic Obstructive Pulmonary Disease

Brazil
Chiesi Farmaceutici S.p.A.

Completed

Lung Bioavailability and Total Systemic Exposure to Beclomethasone17MonoPropionate and Formoterol Across Two Strengths of NEXThaler Inhalation Powder

Asthmatic

United Kingdom
Teva Branded Pharmaceutical Products R&D, Inc.
PPD

Completed

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids

Asthma

United States, Bulgaria, Croatia, Hungary, Israel, Poland, Serbia, Spain, Ukraine
GlaxoSmithKline

Completed

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.

Asthma

United States, Argentina, Germany, Romania, Russian Federation, Ukraine, Chile, Sweden, Mexico, Netherlands, Poland
GlaxoSmithKline

Completed

Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma

Asthma

United States, Russian Federation, Peru, Mexico
GlaxoSmithKline

Completed

To Investigate the Effects of Altering the Time of Day of Dosing (Morning or Evening) With Fluticasone Furoate 100 Micrograms Once Daily Administered Via a Dry Powder Inhaler in Subjects With Asthma

Asthma

Australia
Johns Hopkins University
GlaxoSmithKline

Terminated

Compare the Effects of Fluticasone Furoate Nasal Spray vs Placebo in Patients With Nasal Polypoid Disease

Patients With Nasal Polyps
Organon and Co

Completed

A Study to Evaluate MK0476 and Fluticasone to Control Asthma in Patients With Mild Persistent Asthma (0476-910)

Asthma, Bronchial
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
Scottish Universities Environmental Research Centre
Biotechnology and Biological Sciences Research Council; University of Glasgow

Completed

Investigating Optimal Propionate Delivery to the Colon Using Stable Isotope Labeling

Optimum Propionate Delivery to the Large Intestine

United Kingdom
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pivotal Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
NYU Langone Health
National Institute for Occupational Safety and Health (NIOSH/CDC)

Completed

Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program

Lung Diseases | Medication Compliance

United States
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
Humanis Saglık Anonim Sirketi

Completed

Bioequivalence Study of Azelastine Hydrochloride/ Fluticasone Propionate 137 Microgram/50 Microgram Nasal Spray and Dymista Nasal Spray

Perennial Allergic Rhinitis | Seasonal Allergic Rhinitis

India
Novartis Pharmaceuticals

Completed

A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma

Asthma

China, Germany, United States, India, Korea, Republic of, Romania, South Africa, Croatia, Egypt, Russian Federation, Estonia, Hungary, Poland, Slovakia, Bulgaria, Czechia, Latvia, Guatemala, Serbia, Japan, Mexico, United Kingdom, Li... and more
University of Rostock
GlaxoSmithKline

Completed

Impact of Fluticasone and Salmeterol on Airway Dendritic Cells (DCs) in Smokers

Chronic Obstructive Pulmonary Disease | Smoke-related Lung Diseases

Germany
University of Chicago
GlaxoSmithKline

Completed

Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen

Allergic Rhinitis

United States
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Active, not recruiting

Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers

Bioequivalence

Greece
GlaxoSmithKline

Completed

Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.

Pulmonary Disease, Chronic Obstructive

United States, Korea, Republic of, Chile, Poland, Czech Republic
GlaxoSmithKline

Completed

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects With Allergic Rhinitis

Allergic Rhinitis | Rhinitis, Allergic, Perennial

China
GlaxoSmithKline

Completed

A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-round) Allergic Rhinitis

Rhinitis, Allergic, Perennial

Estonia, United States, Canada, Germany, Slovakia, Russian Federation, Hungary
GlaxoSmithKline

Completed

A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD

Pulmonary Disease, Chronic Obstructive

United States, Germany, Philippines, Thailand, Korea, Republic of, Norway
GlaxoSmithKline

Completed

A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD

Pulmonary Disease, Chronic Obstructive

Taiwan, China, Philippines, Korea, Republic of
Associated Scientists to Help Minimize Allergies
GlaxoSmithKline; Benaroya Research Institute

Completed

Utility of Versican and Hyaluronan Measurement in Induced Sputum as Biomarkers of Asthma

Allergic Asthma

United States
University of Saskatchewan

Completed

Effect of Fluticasone Furoate on Methacholine Challenge

Asthma

Canada
GlaxoSmithKline

Completed

Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study.

Rhinitis, Allergic, Perennial

United States, Argentina, Canada, France, Peru, Italy, Chile
GlaxoSmithKline

Completed

Pharmacokinetics and PharmacoDynamics of GW685698 in Paedeatric Asthmatic Patients

Asthma

United States
GlaxoSmithKline

Completed

Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry.

Asthma

Korea, Republic of, China, Philippines
University of North Carolina, Chapel Hill
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis

Eosinophilic Esophagitis

United States
Novartis
Merck Sharp & Dohme LLC

Completed

Bronchodilatory Efficacy of a Single Dose QMF149 (Indacaterol Maleate/Mometasone Furoate) Via the Twisthaler® Device in Adult Patients With Asthma

Asthma

France, Germany
Children's Hospital of Philadelphia
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Steroids for Pediatric Apnea Research in Kids (SPARK)

Obstructive Sleep Apnea Syndrome

United States
Queen Mary University of London
GlaxoSmithKline; British Lung Foundation

Completed

Withdrawal of Inhaled Corticosteroids in Patients With COPD in Primary Care

Chronic Obstructive Pulmonary Disease

United Kingdom
National Institute of Allergy and Infectious Diseases...
Inner-City Asthma Consortium

Completed

Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations (PROSE)

Asthma

United States
Icahn School of Medicine at Mount Sinai
Bausch Health Americas, Inc.

Recruiting

Duobrii Treatment of Acne Keloidalis Nuchae (AKN)

Acne Keloidalis Nuchae | AKN

United States
GlaxoSmithKline

Completed

Asthma Exacerbation Study

Asthma

United States, Argentina, Germany, Japan, Poland, Romania, Russian Federation, Mexico, Ukraine, Australia, Philippines
GlaxoSmithKline

Completed

Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate and GW642444 Are Processed by the Body in Healthy Subjects

Asthma

Australia
GlaxoSmithKline

Completed

Dose Proportionality Study: Blood Levels of Fluticasone Furoate (FF) and Vilanterol (VI) Following Different Doses of FF/VI Via an Inhaler

Asthma

United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants

Asthma

Ukraine, United States, Argentina, Chile, Mexico, Poland, Russian Federation, Turkey
Boehringer Ingelheim

Completed

The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

Cardiovascular Function in COPD Patients

Pulmonary Disease, Chronic Obstructive

Germany
GlaxoSmithKline

Completed

A Pilot Study In Adults And Adolescents With Irritant (Non-Allergic) Rhinitis

Rhinitis, Allergic, Perennial

Thailand
Merck Sharp & Dohme LLC

Completed

Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors

Advanced Cancer
Brian J Lipworth

Withdrawn

Preventing Tolerance to Oxymetazoline in Allergic Rhinitis

Allergic Rhinitis | Tachyphylaxis | Rhinitis Medicamentosa

United Kingdom
GlaxoSmithKline

Completed

CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.

Asthma

Canada, Bulgaria, Estonia, Spain, Netherlands, Germany, Australia, Austria, Belgium, Finland, Ireland, Latvia, Macedonia, The Former Yugoslav Republic of, New Zealand, United Kingdom
GlaxoSmithKline

Completed

A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis

Rhinitis, Allergic, Perennial

United States
Rush University Medical Center
GlaxoSmithKline

Completed

Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms

Allergic Conjunctivitis to Tree Pollen or Grass Pollen

United States
University of Dundee
NHS Tayside; Chief Scientist Office of the Scottish Government

Completed

Medical Polypectomy and Predictors of Response

Nasal Polyps

United Kingdom
Galderma R&D

Completed

Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis

Plaque Psoriasis

United States
SkyePharma AG
Abbott; MDS Pharma Services

Completed

A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults

Asthma

United States, Chile, Mexico, Peru, Romania, Hungary, South Africa, Ukraine, Poland, Argentina

3

Subscribe